Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2624587 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY2624587 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LY2624587 | DRUG | 6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle. If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days). |
Inclusion Criteria: * Present with histological or cytological evidence of a diagnosis of cancer (solid tumors, lymphoma, or chronic lymphocytic leukemia) that is advanced and/or metastatic. The patient must be, in the judgement of the investigator, an appropriate candidate for experimental therapy...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LY2624587 is an investigational small molecule being studied for the treatment of metastatic cancer. It is in Phase 1 clinical development and has been evaluated in a completed trial involving patients with advanced cancer. The drug is not yet approved and remains under investigation.
LY2624587 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug in patients with metastatic cancer.
LY2624587 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized study. The drug is still investigational and has not been approved for any use.
LY2624587 has been studied in one clinical trial, identified as NCT01139788, titled "A Study of LY2624587 in Patients With Advanced Cancer." This Phase 1 trial was completed and enrolled 56 participants with metastatic cancer in the United States.
LY2624587 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The drug is still in clinical development and has not been authorized for marketing or use in patients outside of clinical research settings.